---
document_datetime: 2025-12-02 05:07:07
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/medicines/human/EPAR/strensiq.html
document_name: strensiq.html
version: success
processing_time: 0.1351592
conversion_datetime: 2025-12-28 15:27:24.451178
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
# Strensiq

[RSS](/en/individual-human-medicine.xml/66288)

##### Authorised

This medicine is authorised for use in the European Union

asfotase alfa Medicine Human Authorised

Page contents

## Page contents

- [Overview](#overview)
- [Product information](#product-info)
- [Product details](#product-details)
- [Authorisation details](#authorisation-details)
- [Assessment history](#assessment-history)
- [News on Strensiq](#news-on)
- [Preventing medication errors](#preventing-medication-errors-1259)
- [More information on Strensiq](#related-medicines)
- [Topics](#topics)

- Application under evaluation
- CHMP opinion
- European Commission decision

## Overview

Strensiq is a medicine used long-term to treat patients with hypophosphatasia that started in childhood. Hypophosphatasia is a rare inherited disease of the bones which can lead to early loss of teeth, malformed bones, frequent bone fractures, and difficulty breathing.

Strensiq contains the active substance asfotase alfa.

Hypophosphatasia is rare, and Strensiq was designated an 'orphan medicine' (a medicine used in rare diseases) on 3 December 2008.

Expand section

Collapse section

## How is Strensiq used?

Strensiq can only be obtained with a prescription and treatment should be started by a doctor who is experienced in managing metabolic or bone disorders.

The medicine is available as a solution for injection. It is given by injection under the skin either six times a week (in a dose of 1 mg per kilogram bodyweight) or three times a week (in a dose of 2 mg/kg). As the amount given depends on the patient's bodyweight, the doctor will need to adjust the dose as the patient's weight changes, particularly in growing children.

For more information about using Strensiq, see the package leaflet or contact your doctor or pharmacist.

## How does Strensiq work?

The enzyme 'tissue non-specific alkaline phosphatase' (ALP) plays a key role in creating and maintaining healthy bones, and managing calcium and phosphate in the body. Patients with hypophosphatasia cannot make enough working ALP, which leads to weak bones. Asfotase alfa, the active substance in Strensiq, is a version of the human ALP enzyme and serves as a replacement, thereby increasing levels of working ALP.

## What benefits of Strensiq have been shown in studies?

Strensiq has been studied in one main study in 13 children between 6 and 12 years of age. Patients were given either 2 mg/kg or 3 mg/kg Strensiq three times a week for 24 weeks. The main measure of effectiveness of the medicine was the improvement in x-ray appearance of the wrists and knee joints before and after treatment with Strensiq. X-rays of children given Strensiq were also compared with similar x-rays available from 16 children who had not received Strensiq ('historical controls'). The study also looked at other measures of effectiveness such as growth in height. This study showed that children given Strensiq had an improvement in their joint structure as demonstrated by x-rays and most of them seemed to gain in height. In the historical controls, most children did not experience similar improvements in their joints or gain in height over a comparable period of time. Additional data from an extension of this study in children aged 13 to 18 years confirmed the initial results.

The effectiveness of Strensiq was also generally supported by several additional small studies. Some of the studies also looked at the dose of 1 mg/kg Strensiq given six times a week.

## What are the risks associated with Strensiq?

The most common side effects with Strensiq (which may affect more than 1 in 10 people) are headache, erythema (reddening of the skin), pain in arms and legs, fever, irritability, injection site reactions (such as pain, rash and itching) and contusion (bruising). For the full list of side effects and restrictions with Strensiq, see the package leaflet.

## Why is Strensiq authorised in the EU?

The European Medicines Agency decided that Strensiq's benefits are greater than its risks and it be authorised for use in the EU.

The Agency noted that hypophosphatasia is a serious and life-threatening disease for which no treatment is authorised. Although the main study was small and did not directly compare Strensiq with another treatment or with untreated patients, the Agency considered that the improvement seen in the bones and the apparent growth was relevant. Given that hypophosphatasia is an extremely rare disease, data in this population will likely remain limited. Regarding safety, injection site reactions and other side effects were considered manageable with the recommendations in place.

Strensiq has been authorised under 'exceptional circumstances'. This is because it has not been possible to obtain complete information about Strensiq due to the rarity of the disease. Every year, the Agency will review any new information that becomes available and this overview will be updated as necessary.

## What information is still awaited for Strensiq?

Since Strensiq has been authorised under exceptional circumstances, the company that markets Strensiq will set up a registry of patients with hypophosphatasia to collect information on the disease and on the long-term safety and effectiveness of Strensiq.

## What measures are being taken to ensure the safe and effective use of Strensiq?

The company that markets Strensiq will provide patients and carers with educational materials to ensure that the medicine is used correctly and to minimise the risk of medication errors. This material will include a self-injection guide for patients, as well as an injection guide for parents or caregivers of children with the condition.

Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Strensiq have also been included in the summary of product characteristics and the package leaflet.

As for all medicines, data on the use of Strensiq is continuously monitored. Side effects reported with Strensiq are carefully evaluated and any necessary action taken to protect patients.

## Other information about Strensiq

Strensiq received a marketing authorisation valid throughout the EU on 28 August 2015.

Strensiq : EPAR - Medicine overview

Reference Number: EMA/716209/2018

English (EN) (102.9 KB - PDF)

**First published:** 28/09/2015

**Last updated:** 26/11/2018

[View](/en/documents/overview/strensiq-epar-medicine-overview_en.pdf)

[Other languages (22)](#file-language-dropdown-99)

български (BG) (126.76 KB - PDF)

**First published:**

28/09/2015

**Last updated:**

26/11/2018

[View](/bg/documents/overview/strensiq-epar-medicine-overview_bg.pdf)

español (ES) (102.11 KB - PDF)

**First published:**

28/09/2015

**Last updated:**

26/11/2018

[View](/es/documents/overview/strensiq-epar-medicine-overview_es.pdf)

čeština (CS) (124.66 KB - PDF)

**First published:**

28/09/2015

**Last updated:**

26/11/2018

[View](/cs/documents/overview/strensiq-epar-medicine-overview_cs.pdf)

dansk (DA) (101.31 KB - PDF)

**First published:**

28/09/2015

**Last updated:**

26/11/2018

[View](/da/documents/overview/strensiq-epar-medicine-overview_da.pdf)

Deutsch (DE) (105.84 KB - PDF)

**First published:**

28/09/2015

**Last updated:**

26/11/2018

[View](/de/documents/overview/strensiq-epar-medicine-overview_de.pdf)

eesti keel (ET) (92.09 KB - PDF)

**First published:**

28/09/2015

**Last updated:**

26/11/2018

[View](/et/documents/overview/strensiq-epar-medicine-overview_et.pdf)

ελληνικά (EL) (126.53 KB - PDF)

**First published:**

28/09/2015

**Last updated:**

26/11/2018

[View](/el/documents/overview/strensiq-epar-medicine-overview_el.pdf)

français (FR) (103.51 KB - PDF)

**First published:**

28/09/2015

**Last updated:**

26/11/2018

[View](/fr/documents/overview/strensiq-epar-medicine-overview_fr.pdf)

hrvatski (HR) (123.28 KB - PDF)

**First published:**

28/09/2015

**Last updated:**

26/11/2018

[View](/hr/documents/overview/strensiq-epar-medicine-overview_hr.pdf)

italiano (IT) (101.77 KB - PDF)

**First published:**

28/09/2015

**Last updated:**

26/11/2018

[View](/it/documents/overview/strensiq-epar-medicine-overview_it.pdf)

latviešu valoda (LV) (126.22 KB - PDF)

**First published:**

28/09/2015

**Last updated:**

26/11/2018

[View](/lv/documents/overview/strensiq-epar-medicine-overview_lv.pdf)

lietuvių kalba (LT) (122.9 KB - PDF)

**First published:**

28/09/2015

**Last updated:**

26/11/2018

[View](/lt/documents/overview/strensiq-epar-medicine-overview_lt.pdf)

magyar (HU) (123.71 KB - PDF)

**First published:**

28/09/2015

**Last updated:**

26/11/2018

[View](/hu/documents/overview/strensiq-epar-medicine-overview_hu.pdf)

Malti (MT) (124.39 KB - PDF)

**First published:**

28/09/2015

**Last updated:**

26/11/2018

[View](/mt/documents/overview/strensiq-epar-medicine-overview_mt.pdf)

Nederlands (NL) (101.33 KB - PDF)

**First published:**

28/09/2015

**Last updated:**

26/11/2018

[View](/nl/documents/overview/strensiq-epar-medicine-overview_nl.pdf)

polski (PL) (125.26 KB - PDF)

**First published:**

28/09/2015

**Last updated:**

26/11/2018

[View](/pl/documents/overview/strensiq-epar-medicine-overview_pl.pdf)

português (PT) (103.06 KB - PDF)

**First published:**

28/09/2015

**Last updated:**

26/11/2018

[View](/pt/documents/overview/strensiq-epar-medicine-overview_pt.pdf)

română (RO) (120.95 KB - PDF)

**First published:**

28/09/2015

**Last updated:**

26/11/2018

[View](/ro/documents/overview/strensiq-epar-medicine-overview_ro.pdf)

slovenčina (SK) (125.42 KB - PDF)

**First published:**

28/09/2015

**Last updated:**

26/11/2018

[View](/sk/documents/overview/strensiq-epar-medicine-overview_sk.pdf)

slovenščina (SL) (121.85 KB - PDF)

**First published:**

28/09/2015

**Last updated:**

26/11/2018

[View](/sl/documents/overview/strensiq-epar-medicine-overview_sl.pdf)

Suomi (FI) (99.44 KB - PDF)

**First published:**

28/09/2015

**Last updated:**

26/11/2018

[View](/fi/documents/overview/strensiq-epar-medicine-overview_fi.pdf)

svenska (SV) (100.85 KB - PDF)

**First published:**

28/09/2015

**Last updated:**

26/11/2018

[View](/sv/documents/overview/strensiq-epar-medicine-overview_sv.pdf)

Strensiq : EPAR - Risk-management-plan summary

English (EN) (63.76 KB - PDF)

**First published:** 28/09/2015

**Last updated:** 28/09/2015

[View](/en/documents/rmp-summary/strensiq-epar-risk-management-plan-summary_en.pdf)

## Product information

Strensiq : EPAR - Product Information

English (EN) (546.96 KB - PDF)

**First published:** 28/09/2015

**Last updated:** 07/02/2024

[View](/en/documents/product-information/strensiq-epar-product-information_en.pdf)

[Other languages (24)](#file-language-dropdown-36)

български (BG) (900.12 KB - PDF)

**First published:**

28/09/2015

**Last updated:**

07/02/2024

[View](/bg/documents/product-information/strensiq-epar-product-information_bg.pdf)

español (ES) (566.34 KB - PDF)

**First published:**

28/09/2015

**Last updated:**

07/02/2024

[View](/es/documents/product-information/strensiq-epar-product-information_es.pdf)

čeština (CS) (616.28 KB - PDF)

**First published:**

28/09/2015

**Last updated:**

07/02/2024

[View](/cs/documents/product-information/strensiq-epar-product-information_cs.pdf)

dansk (DA) (520.86 KB - PDF)

**First published:**

28/09/2015

**Last updated:**

07/02/2024

[View](/da/documents/product-information/strensiq-epar-product-information_da.pdf)

Deutsch (DE) (607.18 KB - PDF)

**First published:**

28/09/2015

**Last updated:**

07/02/2024

[View](/de/documents/product-information/strensiq-epar-product-information_de.pdf)

eesti keel (ET) (592.31 KB - PDF)

**First published:**

28/09/2015

**Last updated:**

07/02/2024

[View](/et/documents/product-information/strensiq-epar-product-information_et.pdf)

ελληνικά (EL) (882.78 KB - PDF)

**First published:**

28/09/2015

**Last updated:**

07/02/2024

[View](/el/documents/product-information/strensiq-epar-product-information_el.pdf)

français (FR) (577.24 KB - PDF)

**First published:**

28/09/2015

**Last updated:**

07/02/2024

[View](/fr/documents/product-information/strensiq-epar-product-information_fr.pdf)

hrvatski (HR) (546.86 KB - PDF)

**First published:**

28/09/2015

**Last updated:**

07/02/2024

[View](/hr/documents/product-information/strensiq-epar-product-information_hr.pdf)

íslenska (IS) (558.85 KB - PDF)

**First published:**

28/09/2015

**Last updated:**

07/02/2024

[View](/is/documents/product-information/strensiq-epar-product-information_is.pdf)

italiano (IT) (914.88 KB - PDF)

**First published:**

28/09/2015

**Last updated:**

07/02/2024

[View](/it/documents/product-information/strensiq-epar-product-information_it.pdf)

latviešu valoda (LV) (578.9 KB - PDF)

**First published:**

28/09/2015

**Last updated:**

07/02/2024

[View](/lv/documents/product-information/strensiq-epar-product-information_lv.pdf)

lietuvių kalba (LT) (557.12 KB - PDF)

**First published:**

28/09/2015

**Last updated:**

07/02/2024

[View](/lt/documents/product-information/strensiq-epar-product-information_lt.pdf)

magyar (HU) (610.84 KB - PDF)

**First published:**

28/09/2015

**Last updated:**

07/02/2024

[View](/hu/documents/product-information/strensiq-epar-product-information_hu.pdf)

Malti (MT) (628.36 KB - PDF)

**First published:**

28/09/2015

**Last updated:**

07/02/2024

[View](/mt/documents/product-information/strensiq-epar-product-information_mt.pdf)

Nederlands (NL) (536.47 KB - PDF)

**First published:**

28/09/2015

**Last updated:**

07/02/2024

[View](/nl/documents/product-information/strensiq-epar-product-information_nl.pdf)

norsk (NO) (866.04 KB - PDF)

**First published:**

28/09/2015

**Last updated:**

07/02/2024

[View](/no/documents/product-information/strensiq-epar-product-information_no.pdf)

polski (PL) (607.79 KB - PDF)

**First published:**

28/09/2015

**Last updated:**

07/02/2024

[View](/pl/documents/product-information/strensiq-epar-product-information_pl.pdf)

português (PT) (566.63 KB - PDF)

**First published:**

28/09/2015

**Last updated:**

07/02/2024

[View](/pt/documents/product-information/strensiq-epar-product-information_pt.pdf)

română (RO) (619.89 KB - PDF)

**First published:**

28/09/2015

**Last updated:**

07/02/2024

[View](/ro/documents/product-information/strensiq-epar-product-information_ro.pdf)

slovenčina (SK) (596.14 KB - PDF)

**First published:**

28/09/2015

**Last updated:**

07/02/2024

[View](/sk/documents/product-information/strensiq-epar-product-information_sk.pdf)

slovenščina (SL) (858.7 KB - PDF)

**First published:**

28/09/2015

**Last updated:**

07/02/2024

[View](/sl/documents/product-information/strensiq-epar-product-information_sl.pdf)

Suomi (FI) (550.86 KB - PDF)

**First published:**

28/09/2015

**Last updated:**

07/02/2024

[View](/fi/documents/product-information/strensiq-epar-product-information_fi.pdf)

svenska (SV) (541.06 KB - PDF)

**First published:**

28/09/2015

**Last updated:**

07/02/2024

[View](/sv/documents/product-information/strensiq-epar-product-information_sv.pdf)

**Latest procedure affecting product information:** II/0065/G 19/10/2023

icon globe

<!-- image -->

This medicine's product information is available in all **official EU languages** . Select 'available languages' to access the language you need.

Product information documents contain:

- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).

Strensiq : EPAR - All Authorised presentations

English (EN) (55.62 KB - PDF)

**First published:** 28/09/2015

**Last updated:** 28/09/2015

[View](/en/documents/all-authorised-presentations/strensiq-epar-all-authorised-presentations_en.pdf)

[Other languages (24)](#file-language-dropdown-340)

български (BG) (64.37 KB - PDF)

**First published:**

28/09/2015

**Last updated:**

28/09/2015

[View](/bg/documents/all-authorised-presentations/strensiq-epar-all-authorised-presentations_bg.pdf)

español (ES) (25.64 KB - PDF)

**First published:**

28/09/2015

**Last updated:**

28/09/2015

[View](/es/documents/all-authorised-presentations/strensiq-epar-all-authorised-presentations_es.pdf)

čeština (CS) (66.41 KB - PDF)

**First published:**

28/09/2015

**Last updated:**

28/09/2015

[View](/cs/documents/all-authorised-presentations/strensiq-epar-all-authorised-presentations_cs.pdf)

dansk (DA) (19.71 KB - PDF)

**First published:**

28/09/2015

**Last updated:**

28/09/2015

[View](/da/documents/all-authorised-presentations/strensiq-epar-all-authorised-presentations_da.pdf)

Deutsch (DE) (27.61 KB - PDF)

**First published:**

28/09/2015

**Last updated:**

28/09/2015

[View](/de/documents/all-authorised-presentations/strensiq-epar-all-authorised-presentations_de.pdf)

eesti keel (ET) (18.64 KB - PDF)

**First published:**

28/09/2015

**Last updated:**

28/09/2015

[View](/et/documents/all-authorised-presentations/strensiq-epar-all-authorised-presentations_et.pdf)

ελληνικά (EL) (65.55 KB - PDF)

**First published:**

28/09/2015

**Last updated:**

28/09/2015

[View](/el/documents/all-authorised-presentations/strensiq-epar-all-authorised-presentations_el.pdf)

français (FR) (19.45 KB - PDF)

**First published:**

28/09/2015

**Last updated:**

28/09/2015

[View](/fr/documents/all-authorised-presentations/strensiq-epar-all-authorised-presentations_fr.pdf)

hrvatski (HR) (62.21 KB - PDF)

**First published:**

28/09/2015

**Last updated:**

28/09/2015

[View](/hr/documents/all-authorised-presentations/strensiq-epar-all-authorised-presentations_hr.pdf)

íslenska (IS) (18.35 KB - PDF)

**First published:**

28/09/2015

**Last updated:**

28/09/2015

[View](/is/documents/all-authorised-presentations/strensiq-epar-all-authorised-presentations_is.pdf)

italiano (IT) (32.33 KB - PDF)

**First published:**

28/09/2015

**Last updated:**

28/09/2015

[View](/it/documents/all-authorised-presentations/strensiq-epar-all-authorised-presentations_it.pdf)

latviešu valoda (LV) (71.45 KB - PDF)

**First published:**

28/09/2015

**Last updated:**

28/09/2015

[View](/lv/documents/all-authorised-presentations/strensiq-epar-all-authorised-presentations_lv.pdf)

lietuvių kalba (LT) (63.09 KB - PDF)

**First published:**

28/09/2015

**Last updated:**

28/09/2015

[View](/lt/documents/all-authorised-presentations/strensiq-epar-all-authorised-presentations_lt.pdf)

magyar (HU) (42.92 KB - PDF)

**First published:**

28/09/2015

**Last updated:**

28/09/2015

[View](/hu/documents/all-authorised-presentations/strensiq-epar-all-authorised-presentations_hu.pdf)

Malti (MT) (70.32 KB - PDF)

**First published:**

28/09/2015

**Last updated:**

28/09/2015

[View](/mt/documents/all-authorised-presentations/strensiq-epar-all-authorised-presentations_mt.pdf)

Nederlands (NL) (32.18 KB - PDF)

**First published:**

28/09/2015

**Last updated:**

28/09/2015

[View](/nl/documents/all-authorised-presentations/strensiq-epar-all-authorised-presentations_nl.pdf)

norsk (NO) (19.45 KB - PDF)

**First published:**

28/09/2015

**Last updated:**

28/09/2015

[View](/no/documents/all-authorised-presentations/strensiq-epar-all-authorised-presentations_no.pdf)

polski (PL) (69.48 KB - PDF)

**First published:**

28/09/2015

**Last updated:**

28/09/2015

[View](/pl/documents/all-authorised-presentations/strensiq-epar-all-authorised-presentations_pl.pdf)

português (PT) (26.11 KB - PDF)

**First published:**

28/09/2015

**Last updated:**

28/09/2015

[View](/pt/documents/all-authorised-presentations/strensiq-epar-all-authorised-presentations_pt.pdf)

română (RO) (65.79 KB - PDF)

**First published:**

28/09/2015

**Last updated:**

28/09/2015

[View](/ro/documents/all-authorised-presentations/strensiq-epar-all-authorised-presentations_ro.pdf)

slovenčina (SK) (66.26 KB - PDF)

**First published:**

28/09/2015

**Last updated:**

28/09/2015

[View](/sk/documents/all-authorised-presentations/strensiq-epar-all-authorised-presentations_sk.pdf)

slovenščina (SL) (41.79 KB - PDF)

**First published:**

28/09/2015

**Last updated:**

28/09/2015

[View](/sl/documents/all-authorised-presentations/strensiq-epar-all-authorised-presentations_sl.pdf)

Suomi (FI) (19.54 KB - PDF)

**First published:**

28/09/2015

**Last updated:**

28/09/2015

[View](/fi/documents/all-authorised-presentations/strensiq-epar-all-authorised-presentations_fi.pdf)

svenska (SV) (20.47 KB - PDF)

**First published:**

28/09/2015

**Last updated:**

28/09/2015

[View](/sv/documents/all-authorised-presentations/strensiq-epar-all-authorised-presentations_sv.pdf)

## Product details

Name of medicine Strensiq Active substance asfotase alfa International non-proprietary name (INN) or common name asfotase alfa Therapeutic area (MeSH) Hypophosphatasia Anatomical therapeutic chemical (ATC) code A16AB

### Pharmacotherapeutic group

Other alimentary tract and metabolism products

### Therapeutic indication

Strensiq is indicated for long-term enzyme replacement therapy in patients with paediatric-onset hypophosphatasia to treat the bone manifestations of the disease.

## Authorisation details

EMA product number EMEA/H/C/003794

Additional monitoring

This medicine is under additional monitoring, meaning that it is monitored even more intensively than other medicines. For more information, see Medicines under [additional monitoring](/node/68821) .

Exceptional circumstances

This medicine was authorised under exceptional circumstances, because the applicant was unable to provide comprehensive data on the efficacy and safety of the medicine under normal conditions of use. This can happen because the condition to be treated is rare or because collection of full information is not possible or is unethical. For more information, see [Pre-authorisation guidance](/node/68554) .

Orphan

This medicine was designated an orphan medicine. This means that it was developed for use against a rare, life-threatening or chronically debilitating condition or, for economic reasons, it would be unlikely to have been developed without incentives. For more information, see [Orphan designation](/node/69983) .

Marketing authorisation holder

Alexion Europe SAS

103-105 rue Anatole France

Opinion adopted 24/06/2015 Marketing authorisation issued 28/08/2015 Revision 17

## Assessment history

Expand section

Collapse section

## Changes since initial authorisation of medicine

Strensiq : EPAR - Procedural steps taken and scientific information after authorisation

English (EN) (285.41 KB - PDF)

**First published:** 09/12/2015

**Last updated:** 07/02/2024

[View](/en/documents/procedural-steps-after/strensiq-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf)

Strensiq-H-C-3794-II-0047 : EPAR - Assessment report - Variation

Adopted

Reference Number: EMA/617078/2020

English (EN) (1.75 MB - PDF)

**First published:** 25/03/2021

[View](/en/documents/variation-report/strensiq-h-c-3794-ii-0047-epar-assessment-report-variation_en.pdf)

Strensiq-H-C-PSUSA-00010421-201807 : EPAR - Scientific conclusions and grounds for the variation to the terms of the marketing authorisation(s)

Reference Number: EMA/241784/2019

English (EN) (67.87 KB - PDF)

**First published:** 13/08/2019

[View](/en/documents/scientific-conclusion/strensiq-h-c-psusa-00010421-201807-epar-scientific-conclusions-and-grounds-variation-terms-marketing-authorisations_en.pdf)

Strensiq : EPAR - Scientific Conclusion

English (EN) (20.48 KB - PDF)

**First published:** 28/09/2015

**Last updated:** 28/09/2015

[View](/en/documents/scientific-conclusion/strensiq-epar-scientific-conclusion_en.pdf)

[Other languages (24)](#file-language-dropdown-965)

български (BG) (114.13 KB - PDF)

**First published:**

28/09/2015

**Last updated:**

28/09/2015

[View](/bg/documents/scientific-conclusion/strensiq-epar-scientific-conclusion_bg.pdf)

español (ES) (26.97 KB - PDF)

**First published:**

28/09/2015

**Last updated:**

28/09/2015

[View](/es/documents/scientific-conclusion/strensiq-epar-scientific-conclusion_es.pdf)

čeština (CS) (106.7 KB - PDF)

**First published:**

28/09/2015

**Last updated:**

28/09/2015

[View](/cs/documents/scientific-conclusion/strensiq-epar-scientific-conclusion_cs.pdf)

dansk (DA) (26.91 KB - PDF)

**First published:**

28/09/2015

**Last updated:**

28/09/2015

[View](/da/documents/scientific-conclusion/strensiq-epar-scientific-conclusion_da.pdf)

Deutsch (DE) (25.5 KB - PDF)

**First published:**

28/09/2015

**Last updated:**

28/09/2015

[View](/de/documents/scientific-conclusion/strensiq-epar-scientific-conclusion_de.pdf)

eesti keel (ET) (26.57 KB - PDF)

**First published:**

28/09/2015

**Last updated:**

28/09/2015

[View](/et/documents/scientific-conclusion/strensiq-epar-scientific-conclusion_et.pdf)

ελληνικά (EL) (105.77 KB - PDF)

**First published:**

28/09/2015

**Last updated:**

28/09/2015

[View](/el/documents/scientific-conclusion/strensiq-epar-scientific-conclusion_el.pdf)

français (FR) (27.04 KB - PDF)

**First published:**

28/09/2015

**Last updated:**

28/09/2015

[View](/fr/documents/scientific-conclusion/strensiq-epar-scientific-conclusion_fr.pdf)

hrvatski (HR) (92.24 KB - PDF)

**First published:**

28/09/2015

**Last updated:**

28/09/2015

[View](/hr/documents/scientific-conclusion/strensiq-epar-scientific-conclusion_hr.pdf)

íslenska (IS) (22.72 KB - PDF)

**First published:**

28/09/2015

**Last updated:**

28/09/2015

[View](/is/documents/scientific-conclusion/strensiq-epar-scientific-conclusion_is.pdf)

italiano (IT) (25.79 KB - PDF)

**First published:**

28/09/2015

**Last updated:**

28/09/2015

[View](/it/documents/scientific-conclusion/strensiq-epar-scientific-conclusion_it.pdf)

latviešu valoda (LV) (103.94 KB - PDF)

**First published:**

28/09/2015

**Last updated:**

28/09/2015

[View](/lv/documents/scientific-conclusion/strensiq-epar-scientific-conclusion_lv.pdf)

lietuvių kalba (LT) (100.63 KB - PDF)

**First published:**

28/09/2015

**Last updated:**

28/09/2015

[View](/lt/documents/scientific-conclusion/strensiq-epar-scientific-conclusion_lt.pdf)

magyar (HU) (97.86 KB - PDF)

**First published:**

28/09/2015

**Last updated:**

28/09/2015

[View](/hu/documents/scientific-conclusion/strensiq-epar-scientific-conclusion_hu.pdf)

Malti (MT) (108.02 KB - PDF)

**First published:**

28/09/2015

**Last updated:**

28/09/2015

[View](/mt/documents/scientific-conclusion/strensiq-epar-scientific-conclusion_mt.pdf)

Nederlands (NL) (27.04 KB - PDF)

**First published:**

28/09/2015

**Last updated:**

28/09/2015

[View](/nl/documents/scientific-conclusion/strensiq-epar-scientific-conclusion_nl.pdf)

norsk (NO) (27.11 KB - PDF)

**First published:**

28/09/2015

**Last updated:**

28/09/2015

[View](/no/documents/scientific-conclusion/strensiq-epar-scientific-conclusion_no.pdf)

polski (PL) (105.43 KB - PDF)

**First published:**

28/09/2015

**Last updated:**

28/09/2015

[View](/pl/documents/scientific-conclusion/strensiq-epar-scientific-conclusion_pl.pdf)

português (PT) (27 KB - PDF)

**First published:**

28/09/2015

**Last updated:**

28/09/2015

[View](/pt/documents/scientific-conclusion/strensiq-epar-scientific-conclusion_pt.pdf)

română (RO) (101.61 KB - PDF)

**First published:**

28/09/2015

**Last updated:**

28/09/2015

[View](/ro/documents/scientific-conclusion/strensiq-epar-scientific-conclusion_ro.pdf)

slovenčina (SK) (72.8 KB - PDF)

**First published:**

28/09/2015

**Last updated:**

28/09/2015

[View](/sk/documents/scientific-conclusion/strensiq-epar-scientific-conclusion_sk.pdf)

slovenščina (SL) (97.65 KB - PDF)

**First published:**

28/09/2015

**Last updated:**

28/09/2015

[View](/sl/documents/scientific-conclusion/strensiq-epar-scientific-conclusion_sl.pdf)

Suomi (FI) (24.78 KB - PDF)

**First published:**

28/09/2015

**Last updated:**

28/09/2015

[View](/fi/documents/scientific-conclusion/strensiq-epar-scientific-conclusion_fi.pdf)

svenska (SV) (26.96 KB - PDF)

**First published:**

28/09/2015

**Last updated:**

28/09/2015

[View](/sv/documents/scientific-conclusion/strensiq-epar-scientific-conclusion_sv.pdf)

## Initial marketing authorisation documents

Strensiq : EPAR - Public assessment report

Adopted

Reference Number: EMA/CHMP/383178/2015

English (EN) (2.13 MB - PDF)

**First published:** 28/09/2015

**Last updated:** 28/09/2015

[View](/en/documents/assessment-report/strensiq-epar-public-assessment-report_en.pdf)

CHMP summary of positive opinion for Strensiq

Adopted

Reference Number: EMA/CHMP/383497/2015

English (EN) (69.05 KB - PDF)

**First published:** 25/06/2015

**Last updated:** 25/06/2015

[View](/en/documents/smop-initial/chmp-summary-positive-opinion-strensiq_en.pdf)

#### News on Strensiq

[First treatment recommended for rare bone disease](/en/news/first-treatment-recommended-rare-bone-disease) 26/06/2015

[Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 22-25 June 2015](/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-22-25-june-2015) 26/06/2015

#### Preventing medication errors

Strensiq: European Medicines Agency recommends measures to ensure safe and effective use

Reference Number: EMA/386551/2015

English (EN) (86.86 KB - PDF)

**First published:** 26/06/2015

**Last updated:** 26/06/2015

[View](/en/documents/medication-error/strensiq-european-medicines-agency-recommends-measures-ensure-safe-and-effective-use_en.pdf)

#### More information on Strensiq

- [EU/3/08/594 - orphan designation for treatment of hypophosphatasia](/en/medicines/human/orphan-designations/eu-3-08-594)
- [EMEA-000987-PIP01-10-M04 - paediatric investigation plan](/en/medicines/human/paediatric-investigation-plans/emea-000987-pip01-10-m04)
- [AN OBSERVATIONAL, LONGITUDINAL, PROSPECTIVE, LONG-TERM REGISTRY OF PATIENTS WITH HYPOPHOSPHATASIA (ALX-HPP-501) - post-authorisation study](https://catalogues.ema.europa.eu/study/47907)

#### Topics

- [Medicines](https://www.ema.europa.eu/en/search?f%5B0%5D=ema_search_topics%3A61)
- [Paediatrics](https://www.ema.europa.eu/en/search?f%5B0%5D=ema_search_topics%3A65)

**This page was last updated on** 07/02/2024

## Share this page

[Back to top](#main-content)